14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
As of Jul 24, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs AVNS. Trailing 12-month operating profitability (RBOT.WS N/A vs AVNS 5.4%) and valuation multiples (RBOT.WS N/M vs AVNS 20.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment44.6% of Rev ($319M)
90D Engineering Disclosures0 Published
Investor FAQ RBOT.WS vs AVNS Key Questions & Quantitative Answers
As of Jul 24, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin). Technically, RBOT.WS sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and AVNS sits in a Neutral phase (RSI 57.0, UNCLASSIFIED options structure).
AVNS leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AVNS at +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $716M for AVNS. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 44.6% of Rev ($319M) (0 disclosures) for AVNS.
AVNS screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus AVNS (-9.2% ROE) capital efficiency.
In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jul 24, 2026. For educational research only; not investment advice.